As global regulators increase public access to clinical and regulatory submissions, disclosure is no longer a question of “if”. The strategic question is whether organizations have the governance discipline to control what is disclosed and why.

When confidential information is exposed unintentionally, the resulting erosion of competitive advantage can materially impact lifecycle value. This can occur even when patents remain fully intact.

The Clinical Transparency Shift

Transparency requirements in Europe and Canada have fundamentally changed the disclosure landscape.

The EU Clinical Trial Regulation (EU No. 536/2014) requires publication of clinical trial information through CTIS, including protocols, assessment documents, and certain trial documentation. EMA Policy 0070 enables proactive disclosure of clinical data submitted for marketing authorization. Health Canada’s Public Release of Clinical Information (PRCI) provides for the public disclosure of clinical reports and supporting data submitted in support of regulatory decisions.

While sponsors may request redaction of commercially confidential information, regulators expect justifications to be narrow, evidence-based, and defensible. Over-redaction invites rejection. Under-redaction creates competitive exposure.

The structural reality is clear: disclosure frameworks are expanding, and the burden of discipline rests with the sponsor.

What Is CI—and Why Executives Should Care

Confidential Information (CI) refers to commercially sensitive, non-public information whose value depends on remaining confidential.

Unlike patents, which derive value from legal protection after disclosure, CI derives value from controlled access. It often includes technical, clinical, manufacturing, or strategic insights that are not patented, not patentable, or intentionally maintained as trade secrets.

In today’s transparency environment, this type of information is routinely embedded within regulatory submissions that may later become subject to public release. The exposure risk does not stem from patent expiration. It stems from inadequate control over what is disclosed and how it is justified.

The Financial Impact

From an enterprise perspective, the financial implications of CI exposure are rarely immediate or dramatic. They tend to unfold gradually through competitive alignment rather than visible disruption.

When development strategies, operational efficiencies, or clinical positioning become more transparent than originally anticipated, competitors can adjust faster. Over time, this can narrow differentiation, reduce pricing flexibility, and compress lifecycle value.

Consider a Phase III asset with a risk adjusted net present value of approximately $2.5 billion. If part of that value is tied to strategic advantage, sequencing insight, or manufacturing efficiency that becomes visible through transparency frameworks, even a modest shift in competitive assumptions can meaningfully affect long term revenue and margin expectations.

There may be no patent dispute and no compliance failure. Instead, value erosion occurs through incremental normalization of competitive advantage. This impact may not show up as a single event, but it can influence forecasts, partner negotiations, and ultimately enterprise valuation.

The cost of disciplined CI governance is typically modest relative to the potential financial consequences of mismanaged disclosure.

Terminology Clarification

Different regulatory frameworks use slightly different terminology. The European Medicines Agency refers to Commercially Confidential Information, or CCI. Health Canada uses the term Confidential Business Information, or CBI.

For purposes of this discussion, Confidential Information is used as a broader, cross-jurisdictional concept referring to commercially sensitive information that organizations seek to protect within transparency frameworks.

Precision in terminology matters, particularly when disclosure decisions may be scrutinized by regulators, partners, or courts.

The Executive Imperative: Transparency Without Value Destruction

Regulatory transparency is now part of the operating reality for life sciences companies. The question for leadership is not whether to disclose, but how to do so in a way that protects long term value.

Confidential Information governance does not belong to a single function. It cuts across regulatory strategy, legal review, clinical development, manufacturing operations, and commercial planning. What appears to be a technical redaction decision can, in certain circumstances, influence competitive positioning and lifecycle assumptions.

In practice, CI decisions are often handled late in the submission process, during compressed review cycles when timelines are tight and teams are focused on approval. That structure increases the likelihood of inconsistency and makes it difficult to step back and evaluate broader strategic implications.

A more disciplined approach starts earlier. It requires clear identification of commercially sensitive information, consistent internal standards, and structured cross functional review before disclosure decisions are finalized.

Transparency is not the issue. Execution is. The organizations that treat CI governance as part of enterprise strategy rather than a regulatory afterthought will be better positioned to protect differentiation over time.

Executive Takeaway

CEO

Disclosure is now part of the competitive landscape in life sciences. The question is whether it is controlled or whether it shapes your competitive position unintentionally. CI governance is not about compliance. It is about protecting differentiation, preserving strategic advantage, and avoiding preventable erosion of long-term value.

CFO

CI exposure may not trigger an immediate financial event, but it can quietly influence competitive timing, pricing flexibility, and long-term margin assumptions. When strategic advantage narrows earlier than expected, lifecycle projections shift. Governance discipline around disclosure decisions helps protect the integrity of financial modeling and valuation assumptions.

Chief Legal Officer

CI governance intersects regulatory compliance and trade secret defensibility. Inconsistent classification or undocumented disclosure decisions can weaken enforcement posture and create exposure under regulatory or litigation scrutiny. Structured review processes and documented rationale strengthen defensibility over time.

Chief IP Officer

Not all competitive advantage is secured through patents. Development sequencing, technical know-how, and operational efficiencies often reside within regulatory submissions. CI governance ensures that disclosure decisions align with broader portfolio strategy and do not unintentionally narrow future optionality.

From Policy to Practice: Technology-Enabled CI Governance

Conceptual agreement on CI governance is not the same as operational consistency. As transparency frameworks expand, organizations require repeatable processes that move beyond late-stage redaction and manual review cycles.

Effective CI governance depends on early identification of commercially sensitive information, consistent internal classification standards, documented justification logic, and visibility across submissions and jurisdictions. Without structured support, these processes can become fragmented and highly dependent on individual interpretation.

Technology enables institutional discipline. Embedding CI identification, review workflows, and documentation standards directly into regulatory processes reduces inconsistency and strengthens defensibility.

The Confidential Information Management (CIM) module within the Medispend Regulatory Science PROTECT platform supports this structured approach. It is designed to align CI identification and review with evolving transparency frameworks while providing traceability and auditability across programs.

As transparency becomes routine, disciplined execution becomes a differentiator.

Transparency will continue to evolve. The organizations that approach CI governance as part of enterprise strategy rather than a procedural requirement will be better positioned to protect differentiation over time. In a disclosure-driven environment, value protection depends less on resisting transparency and more on executing it deliberately.

February 26, 2026

Nirpal Virdee
VP/GM, Regulatory Science

The post Confidential Information (CI): A Board-Level Risk Hiding in Plain Sight appeared first on MediSpend.

What we don’t spend nearly enough time on is checking to make sure WE’RE okay. As anyone who’s ever travelled on a plane knows, you must put your own oxygen mask on first. It’s pretty hard to help your seatmate if you’ve just passed out from lack of oxygen, and the same goes for helping your team. If you exhaust your energy trying to solve every little problem for your coachees, you might find you have no energy left to be a good coach or manager. So how can you make sure your oxygen mask is secure?

We’ve heard a lot of stories from the trenches of coaching over the years, and they tend to boil down to the same sorts of issues. We’ve collected a few pieces of advice for dealing with them.  Here are five:

Don’t work harder than your employees.

In the immortal words of Kenny Rogers, sometimes you “gotta know when to hold ‘em and know when to fold ‘em.” Most of us are in our roles because we are empathetic. We don’t want employees to fail. None of us want to throw in the towel on an employee, and we work very hard to help an employee turn themselves around. That all works. Unless we care more about those things than the employee does. Then it doesn’t.

The reality is, some employees appreciate our effort on their behalf and are right there with us working on their objectives, coming up with ideas for improvement. Others, well, aren’t. It is okay to ask yourself, why should you continue to invest in them more than they are willing to invest in themselves? (Hint: you shouldn’t.) In general, your level of investment in an employee’s development should mirror their own. Anything more or less just isn’t fair to them, you, or to other employees who need your attention and are actually working hard.

Choose which rocks to die on.

Most of us got to be managers because we saw things that needed fixing, and coaches because we want to pay it forward by helping others fix things.  Unfortunately, this desire to fix things can get out of hand, and those who cannot let anything go by may even have earned a reputation as a micromanager. (No names. But you know who you are.)

But even the most alert among us can’t fix everything or win every point. And really, we shouldn’t try to. When we choose which battles to fight (or which rocks to die on) and which to let go, we better focus our energy and save our sanity. We also cue our employees so they know what is most important to us and the organization—and increase their chances of success. Choosing like this gives you permission to prioritize the important things, instead of the frustrating experience of scrapping over every issue or inaccuracy—big or little. Try it!

You’re a boss, not a buddy.

It’s often hard for us, as coaches and managers, to thread the needle between being too distant or being overly familiar with employees. Being too cold can prevent you from connecting to and inspiring employees as a leader. Being too familiar can prevent you from being objective enough to have honest coaching conversations. The balance usually comes when we understand we are a boss, not a friend.

As managers and coaches we must walk a fine line.  This isn’t to say you shouldn’t be friendly. You should. You should also be empathetic. Empathy matters a lot. You can show you are human. But at the end of the day, you are there to do a job for your company: to get the best possible performance from your employees, and to create an environment that helps them develop and grow.  You can be a good boss, or a good friend—but you can’t be both.

Don’t waste time treating symptoms instead of the problem.

As managers, it is easy to get sucked into treating symptoms instead of causes. If an employee is consistently late with a weekly report, for example, it is faster and simpler to criticize them or privately jump to conclusions about why that is happening than to ask what is really going on. But the truth is, unless you ask, you may be addressing the wrong issue.

Being too quick to treat symptoms can make us miss serious underlying problems that may be going unaddressed—or even being exacerbated by your focus on the symptom. If you are too busy chastising Sally for her late reporting, you may be missing the feelings of inadequacy that are making her over-check her numbers—or her crippling belief that you don’t have confidence in her. Behavior is always a symptom. Highlight your concern with the employee and then listen to their side of the story. Don’t interrupt. Ask why. Ask why again. Probe deeper to get at the root cause. And then work from there.

Coach, know thyself.

When you walk into an interaction thinking you know how it will go the chances are very high that your strong belief will cause it to go that way. If you think you’re going to have a good meeting, you’ll do everything possible—consciously or unconsciously— to make that happen. If you are dreading a 1:1 with an employee and are sure it’s going to be horrible, you will undoubtedly convey that emotion and belief to the employee. And chances are it will be horrible—for you both.

As coaches, managers and humans, it’s important for us to understand the biases we bring to every encounter. Our feelings and expectations can determine the outcomes of feedback.  Henry Ford once said, “Whether you think you can or think you can’t, you’re right.” The same is true for us and the people we are coaching. We hold a lot of power as coaches, and whether we think they can or cannot achieve something has a lot to do with their ability to develop. Remember that what you bring into that room or conversation is a huge part of what your employee will leave with. Adjust accordingly.

Coaching is a team effort, and even the best coaches need support. Luckily, you don’t have to go it alone. With the right tools and frameworks, you can refine your approach, save time, and stay energized for what matters most—your people.

Ready to take your Life Sciences coaching practices to the next level? Reach out to our team to explore how the iCoach solution can help you lead more effectively.

February 4, 2026

Ted Power
GM, Field Enablement

The post 5 Survival Lessons from the Life Sciences Coaching Trenches appeared first on MediSpend.

The post State Price Transparency Reporting Solution Checklist Download appeared first on MediSpend.

Traditionally, many organizations have tried to address these needs by purchasing point solutions—individual software tools designed to solve specific problems. On the surface, these systems can look attractive for their specialized functionality. In practice, however, they often introduce fragmentation, inefficiencies and escalating costs that are hard to control.

As a result, SaaS-based companies that offer comprehensive, fully integrated platforms are becoming the preferred choice for business leaders, IT organizations, strategic sourcing teams, and CFOs alike.

This shift is not a passing trend; it represents a strategic evolution driven by measurable business outcomes.

This article explores why integrated SaaS platforms are preferred, along with their benefits and trade-offs while also providing insights for decision-makers across business, IT, procurement, and finance on how to evaluate the best approach for their organizations.

The Growing Complexity of Life Sciences Operations

Life sciences manufacturers operate in one of the most complex business environments in the world. They must simultaneously manage:

• Strict regulatory and commercial compliance requirements
• Large volumes of structured and unstructured data
• Global commercial and supply chain operations
• Multiple stakeholders across R&D, manufacturing, sales, and finance
• Increasing scrutiny on cost control and ROI

Each of these functions generates data that must be accurate, auditable, and accessible in real time. However, when organizations rely on multiple disconnected point solutions, they often encounter:

• Data silos and inconsistent reporting
• Manual data reconciliation and duplicated effort
• Delays in decision-making
• Higher operational and IT overhead
• Increased compliance and security risks

Over time, the cumulative impact of these inefficiencies becomes a strategic disadvantage and a significant cost burden.

Integrated SaaS Platforms: A Holistic Approach to Business Challenges

Integrated SaaS platforms are designed to address multiple business challenges within a single, unified architecture. Rather than stitching together disparate tools, these platforms provide end-to-end capabilities across functional areas, with shared data models, workflows, and analytics.

For life sciences companies, this means:

• A single source of truth for enterprise data, such as for global FMV rates and Tiering
• Seamless workflows across departments for Stakeholder Engagement, Events Management, and Third-Party Due Diligence
• Consistent governance, security, and compliance controls aligned with global requirements and internal policies and procedures
• Faster implementation of new capabilities that support digital and IT strategies
• Scalable infrastructure that can grow with the business while mitigating risk

This approach aligns closely with how life sciences companies actually operate: decisions in one function (such as pricing, contracting, or engagement) directly affect risk, revenue and performance in others.

Why Business Leaders Prefer Integrated Solutions

1. Better Decision-Making Through Unified Data

Chief Commercial Officers, Chief Compliance Officers, Medical Affairs, CFOs, and business leaders rely on timely, accurate insights to drive strategy and execute to enable compliant growth. Integrated platforms eliminate the need to reconcile data across multiple systems, providing real-time visibility into performance metrics across the organization.

With an integrated platform, they no longer need to reconcile data from multiple systems to answer basic questions about spend, engagement activity, or regulatory exposure. Instead of asking, “Which system has that report?” they can focus on, “What action should we take?”

2. Faster Time to Value

Point solutions often require lengthy integration, custom development, and ongoing maintenance before they deliver business value. Integrated SaaS platforms are designed to work together out of the box, shortening implementation timelines and allowing organizations to respond more quickly to regulatory changes or market shifts.

3. Improved Cross-Functional Collaboration

Life sciences success depends on collaboration between commercial, compliance, regulatory, medical affairs, and finance teams. Integrated platforms enable shared workflows and common KPIs, reducing friction and improving alignment across the organization.

Why IT Organizations Favor Integrated SaaS Platforms

1. Reduced Integration Complexity

Chief Information Officers and IT teams are under pressure to simplify their technology landscape.. Each point solution introduces new APIs, data mappings, security considerations, and upgrade cycles.

Consolidating onto an integrated platform helps IT:

• Reduce the number of vendors to manage

• Standardize data and security models
• Streamline upgrades, validation and maintenance

2. Enhanced Security and Compliance

Life sciences companies must meet strict regulatory standards, including data privacy, validation, and audit requirements. Managing compliance across multiple vendors increases risk.

Integrated platforms enable centralized security controls, consistent validation frameworks, and unified audit trails, which make inspections and audits more straightforward.

3. Scalability and Futureproofing

As organizations grow or expand into new markets, IT needs to scale systems quickly. Integrated SaaS platforms are designed for scalability, allowing companies to add users, modules, or geographies without re-architecting their entire technology stack.

Strategic Sourcing and Procurement: Fewer Vendors, Greater Value

From a strategic sourcing perspective, managing dozens of point solution vendors creates unnecessary complexity. Each vendor requires separate contracts, negotiations, renewals, and performance management.

Integrated SaaS platforms offer procurement teams:

• Vendor consolidation and stronger strategic relationships
• More predictable pricing and clearer service levels
• Reduced administrative overhead on renewals, legal review, and vendor management

While the initial investment may appear higher than a single point solution, the total cost of ownership (TCO) is often significantly lower when integration, maintenance, and operational costs are considered.

CFO Perspective: Financial Transparency and ROI

Chief Financial Officers are increasingly involved in technology decisions, and for good reason. Fragmented systems obscure true costs and limit financial visibility.

Integrated SaaS platforms improve:

• Cost attribution across functions and business units
• Forecasting and budgeting for technology operations
• Measurement of ROI on software and services investments

By aligning technology investments with business outcomes, CFOs gain greater confidence that software spend is driving measurable value.

Pros and Cons: Integrated SaaS vs. Point Solutions

Pros of Integrated SaaS Platforms

• Unified data and analytics across functions
• Reduced integration and maintenance costs
• Faster decision-making and response to change
• Stronger compliance, security, and audit readiness
• Stronger cross-functional alignment and governance
• Vendor consolidation and clearer accountability
• Better business outcomes

Cons of Point Solutions

• Data silos and inconsistent or conflicting reporting
• Higher integration and maintenance costs over time
• More complex vendor and contract management
• Greater security and compliance risk
• Slower, less confident enterprise-wide decision-making

Making the Right Choice for Your Organization

For life sciences companies, the decision is no longer just about software feature checklists. It is about operating model, scalability, reducing risk, long-term value, and better business outcomes. While point solutions may still have a role in niche scenarios, the overwhelming preference among leading organizations is shifting toward comprehensive, integrated SaaS platforms.

By choosing vendors that understand the unique challenges of pharmaceutical, biotech, and medical device industries—and that offer fully integrated, enterprise-grade solutions—companies can simplify their technology landscape, reduce risk, and unlock greater business performance.

If your organization is evaluating whether to consolidate systems or invest in a more integrated platform, now is the ideal time to assess your current landscape, identify gaps and redundancies, and build a phased roadmap toward a more unified, future-ready architecture. To explore how an integrated SaaS platform can support your specific compliance and growth objectives, contact our team to schedule a brief discovery discussion.

January 20, 2026

Seth Houston
Chief Commercial Officer

The post Why Life Sciences Companies Are Choosing Integrated SaaS Platforms Over Point Solutions to Ensure Compliant Growth appeared first on MediSpend.

The combined company offers a comprehensive suite of enterprise software and services for global regulatory and commercial compliance, medical affairs, field enablement and revenue management solutions designed to empower life sciences companies to grow their business compliantly.

While the company will continue under the MediSpend name, the merger marks a significant evolution of the brand. Medispend is introducing a refreshed visual identity, including a new logo, color palette, and emblem, to reflect its expanded capabilities, forward-looking vision, and commitment to innovation.

The unified MediSpend is positioned to become a single, trusted vendor providing the most comprehensive suite of life sciences compliance, stakeholder engagement, medical affairs, field enablement, and revenue management solutions in the industry. By combining the strengths of both organizations, MediSpend now offers an expanded product portfolio supported by advanced technology, enhanced analytics, and scalable managed services designed to meet the evolving needs of global life sciences organizations.

“This merger represents a pivotal moment for our customers and the industry,” said Leigh Powell, executive chairman of Medispend. “By bringing together RLDatix Life Sciences and MediSpend under one brand, we are accelerating our ability to deliver innovative, purpose-built solutions that help customers reduce risk, streamline operations, and confidently grow their business in an increasingly complex regulatory environment.”

Christopher Gingras, president of Medispend, said, “The new Medispend brand reflects a clear future vision, which includes our continued investment in innovative technology, expanded managed services, and a relentless focus on customer success.”

Existing customers will continue to receive uninterrupted service and support, while benefiting from the expanded capabilities and resources of the combined organization.

About Medispend:

Medispend is a global leading provider of SaaS solutions that deliver secure, scalable and intuitive cloud-based software enabling life sciences organizations to grow their business compliantly. More than 400 pharmaceutical, biotech and medical technology companies from around the world rely on Medispend to reduce compliance risk, improve customer engagements, optimize operations and make data driven decisions. Our mission is to help customers scale confidently and compliantly in an increasingly complex healthcare environment. For more information, visit www-stg.medispend.com.

Media Contact:
Seth Houston

Chief Commercial Officer
shouston@medispend.com
(215) 779-2415

The post Medispend and RLDatix Life Sciences Complete Merger, Uniting Under the Medispend Brand to Create The Leading Life Sciences Compliance Software-as-a-Service Provider appeared first on MediSpend.

The post State Price Transparency Solution Summary Download appeared first on MediSpend.

Fair Market Value (FMV) remains a central focus within the life sciences industry, as underscored at the recent Pharmaceutical and Medical Device Ethics and Compliance Congress. As the regulatory environment continues to evolve, companies are under increasing scrutiny regarding the appropriateness of compensation paid to healthcare professionals (HCPs). Corporate integrity agreements repeatedly highlight deficiencies in FMV methodologies, reinforcing the importance of strong governance, defensible processes, and ongoing monitoring. Because FMV determinations directly intersect with anti-kickback statute risk, compliance professionals must regularly evaluate whether their policies, procedures, and operational practices are both current and effective.

A foundational component of FMV governance is the framework used to assess an HCP’s skills, experience and qualifications. When developing tiering questions or criteria, organizations should ensure that all measures are objective, evidence-based, defensible and applied consistently. FMV determinations must never be influenced by prescribing volume or referral potential. Instead, tiering tools should reflect the HCP’s expertise and professional accomplishments. Common criteria include academic appointments, publication and presentation history, clinical research involvement, leadership roles and depth of specialty experience. Additional considerations include the HCP’s clinical specialty, the country of licensure and whether the HCP possesses rare disease or highly specialized expertise. Rate cards—centralized lists of approved compensation rates—should be benchmarked against credible market data and reevaluated periodically. Organizations must also determine which internal stakeholders are best suited to perform HCP tiering, balancing subject-matter expertise with independence from commercial influence.

Travel time

Compensating HCPs for travel time presents unique challenges, and companies should adopt methodologies that are fair, transparent and aligned with FMV principles. Travel time represents compensated professional activity, as HCPs are unavailable to treat patients while traveling for company-sponsored services. Approaches vary widely. Some organizations compensate door-to-door travel at 100 percent of the HCP’s FMV hourly rate, others adopt a 50 percent reduced rate, and still others apply hybrid models depending on distance or duration. One practice discussed at the congress involved the use of a flat, FMV-supported travel flat rate calculated based on round‑trip mileage, offering consistency and administrative simplicity.

Preparation time

Preparation time remains a consistently challenging area within FMV frameworks. Companies should develop a detailed standard operating procedure that outlines permissible preparation activities, reasonable time expectations and the documentation required to support claimed hours. Preparation time should reflect what is necessary for the HCP to meet the defined expectations of their engagement—no more, no less.

Where possible, organizations may “hard‑code” preparation time ranges by event type, requiring elevated approval for requests that exceed those thresholds. Special consideration should be given to chairs or moderators of major scientific events, whose responsibilities often require substantially more preparation than standard participants. Establishing clear, defensible assumptions reduces variability, enhances consistency and strengthens audit readiness.

Social media influencers

FMV considerations for social media influencers continue to evolve, and industry standards are far less mature than those governing traditional HCP engagements. Unlike conventional FMV frameworks, rate cards generally do not exist in this space, and factors such as content development and platform reach may be relevant depending on the nature of the services provided. The most effective approach is to establish defensible principles tailored to influencer‑based engagement, focusing on the content created, the expertise of the influencer (e.g., HCP, patient, caregiver) and the complexity and time required for the requested activity.

Companies should distinguish between original content development, which typically warrants higher compensation, and simple reposting, which may require significantly less time and expertise. Any original content should undergo review and approval by the appropriate medical, legal and regulatory stakeholders to ensure accuracy and compliance.

Conclusion

As the FMV landscape continues to mature, life sciences companies must proactively refine their compensation methodologies to ensure compliance, fairness and operational consistency. Strong governance, objective and defensible tiering tools, thoughtful approaches to travel and preparation time, and emerging best practices for social media influencers all contribute to a comprehensive FMV framework. By continuously assessing and strengthening these elements, organizations can reduce risk, enhance transparency, and maintain the trust of regulators, HCP partners and the broader healthcare community.

For more information on fair market value governance or to discuss how we can support your compliance initiatives, contact us today.

November 18, 2025

Jay Ward
Life Sciences Solutions Director

The post Making Sense of FMV: Strategies for the Life Sciences Industry appeared first on MediSpend.

September 02, 2025 – MediSpend and RLDatix Life Sciences, a subsidiary of RLDatix, today announced a definitive agreement to merge, creating a new unified company at the forefront of life sciences innovation and compliance. The new company offers the most comprehensive suite of software, data and workflow tools to support the entire lifecycle for global compliance, transparency, and sales enablement for the life sciences industry. The combined company currently serves over 300 pharmaceutical, biotech, and medical device companies worldwide.

Backed by Five Arrows (the alternative assets arm of Rothschild & Co), Susquehanna Growth Equity, TA Associates, and Nordic Capital, the new company brings together RLD Life Sciences’ expertise in providing services for pharmaceutical product development, commercialization, and distribution with robust compliance, and sales enablement alongside MediSpend’s best-in-class transparency, stakeholder engagement, and data solutions supporting both commercial and clinical stakeholders.

MediSpend brings innovative technology that enables life sciences companies to grow their businesses compliantly through SaaS-based Stakeholder Engagement, Event Management, Spend Transparency, and advanced Clinical Data Document Anonymization and Redaction capabilities.

RLDatix Life Sciences contributes unmatched subject matter expertise and market-leading skills by empowering life sciences companies to master complexity, mitigate risk, and continually exceed the standards of compliance – from Government Pricing to Learning and Development.

This strategic integration empowers pharmaceutical and life sciences companies to accelerate innovation, ensure regulatory integrity, and bring high-quality healthcare solutions to market more efficiently and ethically, while adhering to the highest compliance standards.

“This combination builds on our commitment to delivering innovative software, services, and support to life sciences companies across the globe,” said Michael Allelunas, CEO of the new company. “Together, we combine our purpose-built platform of solutions to streamline global compliance, drive operational efficiency, and unlock new opportunities for our customers.”

Leigh Powell, Chairman of the new company, added: “This merger represents a powerful alignment of mission and capability. We are excited to bring together our technologies, teams, and customers to provide the go-forward partner of choice for the life sciences industry. Our shared focus on innovation and client success will continue to guide us.”

Clients and partners can expect uninterrupted service, increased investment in product development, and a clear commitment to a seamless integration experience. The company will continue to operate under both brand names in the near term, with a long-term vision to unify under a new common name which will be announced in the coming months.

About MediSpend

MediSpend’s leading solutions empower life sciences companies to grow their business compliantly through top-rated solutions and client services. MediSpend provides commercial compliance solutions for the largest pharmaceutical, medical device and dental companies as well as emerging biotech companies across the world. MediSpend is headquartered in Portsmouth, N.H., with offices in Minnesota, New York, Pennsylvania and the Netherlands. Visit MediSpend online at www-stg.medispend.com.

About RLDatix Life Sciences

RLDatix Life Sciences, a subsidiary of RLDatix, is a leading provider of comprehensive solutions in the life sciences industry. Formed through the integration of Porzio Life Sciences, iContracts, and iCoachFirst, RLDatix Life Sciences offers cutting-edge compliance solutions, and strategic coaching and training services. The company is committed to driving excellence and innovation within the life sciences industry. Visit www.rldatixlifesciences.com to learn more.

About Five Arrows

Five Arrows is the alternative assets arm of Rothschild & Co and has over €29 billion in assets under management, with offices in Paris, London, New York, Los Angeles, San Francisco, and Luxembourg.

With more than €10 billion of assets under management, the corporate private equity business of Five Arrows is focused on investing in companies with strong management teams; business models with high visibility of organic unit volume growth and strong unit economics; and multiple operational levers that can be used to unlock latent value. Sectors are limited to data and software, technology–enabled business services, and healthcare.

For more information, visit: www.rothschildandco.com/en/five-arrows/corporate-private-equity

About SGE

Susquehanna Growth Equity (“SGE”) is an entrepreneur-centric growth equity fund with flexible capital and time horizons. SGE is exclusively focused on growth-stage software, services, internet, and information services companies. The firm has invested in over $5 billion in 100+ market-leading technology and services companies over the last 19 years and has portfolio companies across the US, Canada, Europe, and Israel. SGE is backed by a unique and patient source of capital, enabling the firm to give entrepreneurs and management teams freedom and flexibility to manage growth. To learn more, please visit www.sgep.com.

About TA

TA is a leading global private equity firm focused on scaling growth in profitable companies. Since 1968, TA has invested in more than 560 companies across its five core sectors – technology, business services, financial services, healthcare and consumer. Leveraging its deep industry expertise and strategic resources, TA collaborates with management teams worldwide to help high-quality companies deliver lasting value. The firm has raised $65 billion in capital to date and has more than 160 investment professionals across offices in Boston, Menlo Park, Austin, London, Mumbai and Hong Kong. More information about TA can be found at www.ta.com.

About Nordic Capital

Nordic Capital is a leading sector-specialist private equity investor with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a long history. Focus sectors are Healthcare, Technology & Payments, Financial Services, and Services & Industrial Tech. Key regions are Europe and globally for Healthcare and Technology & Payments investments. Since inception in 1989, Nordic Capital has invested c. EUR 30 billion in over 150 investments. The committed capital is principally provided by global institutional investors such as pension funds. Nordic Capital Advisors have local offices in Sweden, the UK, the US, Germany, Denmark, Finland, Norway, and South Korea. For more information see www.nordiccapital.com.

“Nordic Capital” refers to, depending on the context, any, or all, Nordic Capital branded entities, vehicles, structures, and associated entities. The general partners and/or delegated portfolio managers of Nordic Capital’s entities and vehicles are advised by several non-discretionary sub-advisory entities, any or all of which are referred to as “Nordic Capital Advisors”.

Media Contact

Seth Houston
shouston@medispend.com

The post MediSpend and Life Sciences Subsidiary of RLDatix Merge to Form Leading Global Provider of Regulatory and Compliance SaaS Solutions for Life Sciences appeared first on MediSpend.

The post From Hot Mess to High-Performing: Building a Scalable Third-Party Due Diligence Program appeared first on MediSpend.

Alucio’s BEACON platform enables seamless and compliant content engagement across medical affairs, clinical affairs, and market access, empowering field teams to deliver dynamic, personalized scientific interactions with healthcare professionals (HCPs) and organizations.  This strategic move supports MediSpend’s ongoing mission to empower life sciences companies to grow their business compliantly while delivering more meaningful stakeholder interactions and insights.

Driving Innovation with AI-Powered Scientific Engagement
Alucio brings advanced AI-powered capabilities that transform how medical affairs teams manage and share scientific information. By integrating artificial intelligence into content management and HCP engagement workflows, the MediSpend platform offers expanded functionality to personalize interactions, streamline content distribution and generate real-time insights. These enhancements support high-impact, compliant scientific exchange on a global scale.

“This acquisition brings valuable innovation into the MediSpend platform,” said Leigh Powell, Executive Chairman of MediSpend. “With these added capabilities, we’re strengthening our ability to support medical affairs teams with smarter tools for managing content and delivering compliant, high-quality scientific communications.”

Delivering Value Across the Life Sciences Industry
By combining MediSpend’s trusted compliance infrastructure with Alucio’s AI-driven communication capabilities, clients gain a cohesive solution that supports compliant, efficient and insight-driven engagement across both commercial and medical teams. Clients will benefit from:

• Smarter Scientific Exchange: AI-assisted delivery enables tailored, compliant interactions between MSLs and HCPs.
• Seamless Content Management: Efficient tools for organizing, presenting and sharing scientific information that are designed to meet both internal needs and regulatory standards.
• Actionable Analytics: Built-in intelligence provides visibility into engagement metrics and content performance, enabling teams to make data-driven decisions.

“We’re excited to join MediSpend and expand the reach of our technology,” said Dave Gulezian, CEO of Alucio. “Together, we’ll deliver next-generation solutions that elevate how medical affairs teams communicate and engage with HCPs in a compliant manner.”

Strengthening MediSpend’s Leadership in Life Sciences Technology
The integration of BEACON into the MediSpend platform will create a seamless solution for life sciences companies seeking to unify compliance, transparency, and engagement functions—an increasingly critical need in today’s complex regulatory environment.

About MediSpend
MediSpend’s best-in-class solutions empower life sciences companies to grow their business compliantly through top-rated solutions and client services. MediSpend provides commercial compliance solutions for the largest pharmaceutical, medical device and dental companies as well as emerging biotech companies across the world. MediSpend is headquartered in Portsmouth, N.H., with offices in Minnesota, New York, Pennsylvania and the Netherlands. Visit MediSpend online at www-stg.medispend.com.

About Alucio
Alucio is dedicated to the development of innovative software applications specifically for the life sciences industry. Alucio’s flagship product, Beacon, is a modern, AI-enabled scientific exchange platform that enhances scientific dialogue and engagement between life science companies and healthcare professionals. For more information, please visit the company’s website at http://www.alucio.io.

Media Contact
Seth Houston
Chief Commercial Officer
MediSpend
Email: shouston@medispend.com
Phone: +1 (215) 779-2415

The post MediSpend Acquires Alucio to Expand AI-Enabled Stakeholder Engagement Capabilities appeared first on MediSpend.